Experimental pill daraxonrasib nearly doubles survival time for advanced pancreatic cancer patients
By
LAURAN NEERGAARD AP medical writer
Sesame, salt, and substance. A flagship bake.
Summary
Researchers reported that daraxonrasib, a novel daily pill, helped people with advanced pancreatic cancer live longer by blocking a mutated protein that fuels tumor growth in over 90% of cases. The drug nearly doubled survival time, marking a significant step forward in treating one of the deadliest cancers, though it does not cure the disease.
Key quotes
· 2 pulledWhile not curing the cancer, it is a very large step forward.
The daily pills nearly doubled survival time, with fewer
You might also wanna read
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
A clinical trial has shown that a daily pill called daraxonrasib can double survival time for patients with advanced pancreatic cancer, one
theguardian.com·12d ago
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Spanish researchers have developed a new therapy protocol that could revolutionize pancreatic cancer treatment. Pancreatic cancer is notorio
nypost.com·4mo ago
Study Finds GLP-1 Drugs Associated with 58% Lower Mortality in Colon Cancer Patients
A study analyzing over 6,800 colon cancer patients across University of California Health sites found that patients taking GLP-1 medications
TAR-200 Drug System Eliminates Bladder Cancer in 82% of Resistant Patients
A new drug-releasing system, TAR-200, has shown remarkable success in treating high-risk non-muscle-invasive bladder cancer, eliminating tum
news.keckmedicine.org·10mo ago
Personalized mRNA Cancer Vaccine Shows 49% Risk Reduction at 5-Year Follow-up
Moderna and Merck report promising 5-year follow-up results for their personalized mRNA cancer vaccine combined with Keytruda immunotherapy.
arstechnica.com·4mo ago
AI Advances in Drug Discovery: From Data Integration to Dual-Action Cancer Drug Design
The article discusses recent advancements in AI-driven drug discovery, highlighting two key developments: 1) Analytica 2026, an event focuse
drugtargetreview.com·4mo ago